These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 12634732)
1. Refractory Evans' syndrome treated with allogeneic SCT followed by DLI. Demonstration of a graft-versus-autoimmunity effect. Marmont AM; Gualandi F; Van Lint MT; Bacigalupo A Bone Marrow Transplant; 2003 Mar; 31(5):399-402. PubMed ID: 12634732 [TBL] [Abstract][Full Text] [Related]
2. Catastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal hemolytic-uremic syndrome. Marmont AM; Gualandi F; Occhini D; Morandi F; Ferretti E; Pezzolo A; Strada P; Ravetti JL; Pistoia V; Falanga A; Bacigalupo A Autoimmunity; 2006 Sep; 39(6):505-11. PubMed ID: 17060030 [TBL] [Abstract][Full Text] [Related]
3. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Talmadge JE Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168 [TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
6. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Xia G; Truitt RL; Johnson BD Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723 [TBL] [Abstract][Full Text] [Related]
7. Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Kojima R; Kami M; Kim SW; Murashige N; Kishi Y; Hori A; Imataki O; Hamaki T; Sakiyama M; Masuo S; Fujisawa Y; Makimoto A; Heike Y; Tanosaki R; Takaue Y Bone Marrow Transplant; 2003 Aug; 32(4):439-42. PubMed ID: 12900783 [TBL] [Abstract][Full Text] [Related]
9. Treatment of severe Evans syndrome with an allogeneic cord blood transplant. Raetz E; Beatty PG; Adams RH Bone Marrow Transplant; 1997 Sep; 20(5):427-9. PubMed ID: 9339762 [TBL] [Abstract][Full Text] [Related]
10. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270 [TBL] [Abstract][Full Text] [Related]
11. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466 [TBL] [Abstract][Full Text] [Related]
12. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation. Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931 [TBL] [Abstract][Full Text] [Related]
14. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice. Du B; Li DP; Xu KL; Pan XY Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128 [TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Chan GW; Foss FM; Klein AK; Sprague K; Miller KB Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114 [TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R Clin Transpl; 2003; ():275-82. PubMed ID: 15387119 [TBL] [Abstract][Full Text] [Related]
18. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285 [TBL] [Abstract][Full Text] [Related]
19. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies. Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392 [TBL] [Abstract][Full Text] [Related]